Modulation of human T-cell differentiation markers by 12-O-tetradecanoylphorbol-13-acetate. 1981

K Nagasawa, and B E Chechik, and E W Gelfand, and S Sengupta, and M Letarte, and T W Mak

The analysis of seven differentiation markers following incubation with the tumor promotor 12-O-tetradecanoylphorbol-13-acetate (TPA) was examined in the human leukemic T-cell line MOLT-3. Significant changes were observed in the activity of the markers terminal deoxynucleotidyl transferase (TdT). spontaneous proliferation and the ability of these cells to bind sheep erythrocytes. Levels of human thymus-leukemia-associated antigen (HThy-L) recently identified as a low molecular weight form of adenosine deaminase (ADA), were reduced by about 50%. No significant changes were observed in ecto-5'-nucleotidase [5'-NT) activities, in the proliferative response to PHA, or in the expression of IA-like antigens. These data and the time kinetics of the changes suggest that following incubation of these T-lymphoblasts with TPA there is a sequential loss of TdT, loss of the capacity for spontaneous proliferation, and the appearance of receptors for sheep erythrocytes. Subsequently there is a decrease in the level of HThy-L/ADA. This sequence appears to follow that proposed for prethymic precursor T-cell differentiation following activation with thymic epithelium.

UI MeSH Term Description Entries
D007942 Leukemia, Experimental Leukemia induced experimentally in animals by exposure to leukemogenic agents, such as VIRUSES; RADIATION; or by TRANSPLANTATION of leukemic tissues. Experimental Leukemia,Experimental Leukemias,Leukemia Model, Animal,Leukemias, Experimental,Animal Leukemia Model,Animal Leukemia Models,Leukemia Models, Animal
D009708 Nucleotidases A class of enzymes that catalyze the conversion of a nucleotide and water to a nucleoside and orthophosphate. EC 3.1.3.-.
D010704 Phorbols The parent alcohol of the tumor promoting compounds from CROTON OIL (Croton tiglium). Tigliane,Tiglianes
D010835 Phytohemagglutinins Mucoproteins isolated from the kidney bean (Phaseolus vulgaris); some of them are mitogenic to lymphocytes, others agglutinate all or certain types of erythrocytes or lymphocytes. They are used mainly in the study of immune mechanisms and in cell culture. Kidney Bean Lectin,Kidney Bean Lectins,Lectins, Kidney Bean,Phaseolus vulgaris Lectin,Phaseolus vulgaris Lectins,Phytohemagglutinin,Hemagglutinins, Plant,Lectin, Kidney Bean,Lectin, Phaseolus vulgaris,Lectins, Phaseolus vulgaris,Plant Hemagglutinins
D002471 Cell Transformation, Neoplastic Cell changes manifested by escape from control mechanisms, increased growth potential, alterations in the cell surface, karyotypic abnormalities, morphological and biochemical deviations from the norm, and other attributes conferring the ability to invade, metastasize, and kill. Neoplastic Transformation, Cell,Neoplastic Cell Transformation,Transformation, Neoplastic Cell,Tumorigenic Transformation,Cell Neoplastic Transformation,Cell Neoplastic Transformations,Cell Transformations, Neoplastic,Neoplastic Cell Transformations,Neoplastic Transformations, Cell,Transformation, Cell Neoplastic,Transformation, Tumorigenic,Transformations, Cell Neoplastic,Transformations, Neoplastic Cell,Transformations, Tumorigenic,Tumorigenic Transformations
D003114 Colony-Forming Units Assay A cytologic technique for measuring the functional capacity of stem cells by assaying their activity. Clonogenic Cell Assay,Stem Cell Assay,Clonogenic Cell Assays,Colony Forming Units Assays,Colony-Forming Units Assays,Stem Cell Assays,Assay, Clonogenic Cell,Assay, Colony-Forming Units,Assay, Stem Cell,Assays, Clonogenic Cell,Assays, Colony-Forming Units,Assays, Stem Cell,Colony Forming Units Assay
D003561 Cytarabine A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472) Ara-C,Arabinofuranosylcytosine,Arabinosylcytosine,Cytosine Arabinoside,Aracytidine,Aracytine,Cytarabine Hydrochloride,Cytonal,Cytosar,Cytosar-U,beta-Ara C,Ara C,Arabinoside, Cytosine,Cytosar U,beta Ara C
D004247 DNA A deoxyribonucleotide polymer that is the primary genetic material of all cells. Eukaryotic and prokaryotic organisms normally contain DNA in a double-stranded state, yet several important biological processes transiently involve single-stranded regions. DNA, which consists of a polysugar-phosphate backbone possessing projections of purines (adenine and guanine) and pyrimidines (thymine and cytosine), forms a double helix that is held together by hydrogen bonds between these purines and pyrimidines (adenine to thymine and guanine to cytosine). DNA, Double-Stranded,Deoxyribonucleic Acid,ds-DNA,DNA, Double Stranded,Double-Stranded DNA,ds DNA
D004253 DNA Nucleotidylexotransferase A non-template-directed DNA polymerase normally found in vertebrate thymus and bone marrow. It catalyzes the elongation of oligo- or polydeoxynucleotide chains and is widely used as a tool in the differential diagnosis of acute leukemias in man. EC 2.7.7.31. Terminal Addition Enzyme,Terminal Deoxyribonucleotidyltransferase,Deoxynucleotidyl Transferase,Deoxynucleotidyltransferase,Desoxynucleotidyl Transferase,Desoxynucleotidyltransferase,Tdt Antigen,Terminal Deoxynucleotidyl Transferase,Terminal Deoxyribonucleotidyl Transferase,Addition Enzyme, Terminal,Antigen, Tdt,Deoxynucleotidyl Transferase, Terminal,Deoxyribonucleotidyl Transferase, Terminal,Deoxyribonucleotidyltransferase, Terminal,Enzyme, Terminal Addition,Nucleotidylexotransferase, DNA,Transferase, Deoxynucleotidyl,Transferase, Desoxynucleotidyl,Transferase, Terminal Deoxynucleotidyl,Transferase, Terminal Deoxyribonucleotidyl
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

K Nagasawa, and B E Chechik, and E W Gelfand, and S Sengupta, and M Letarte, and T W Mak
June 1990, Cancer research,
K Nagasawa, and B E Chechik, and E W Gelfand, and S Sengupta, and M Letarte, and T W Mak
November 1988, Cancer research,
K Nagasawa, and B E Chechik, and E W Gelfand, and S Sengupta, and M Letarte, and T W Mak
November 1983, Experimental hematology,
K Nagasawa, and B E Chechik, and E W Gelfand, and S Sengupta, and M Letarte, and T W Mak
March 1986, Laboratory investigation; a journal of technical methods and pathology,
K Nagasawa, and B E Chechik, and E W Gelfand, and S Sengupta, and M Letarte, and T W Mak
September 1992, British journal of cancer,
K Nagasawa, and B E Chechik, and E W Gelfand, and S Sengupta, and M Letarte, and T W Mak
February 1987, Cancer letters,
K Nagasawa, and B E Chechik, and E W Gelfand, and S Sengupta, and M Letarte, and T W Mak
July 1995, Zhonghua yi xue za zhi = Chinese medical journal; Free China ed,
K Nagasawa, and B E Chechik, and E W Gelfand, and S Sengupta, and M Letarte, and T W Mak
May 1982, Immunology letters,
K Nagasawa, and B E Chechik, and E W Gelfand, and S Sengupta, and M Letarte, and T W Mak
July 1989, The Journal of investigative dermatology,
K Nagasawa, and B E Chechik, and E W Gelfand, and S Sengupta, and M Letarte, and T W Mak
August 1982, Cellular immunology,
Copied contents to your clipboard!